Larimar Therapeutics, Inc. (LRMR)
LRMR Stock Price Chart
Explore Larimar Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze LRMR price movements and trends.
LRMR Company Profile
Discover essential business fundamentals and corporate details for Larimar Therapeutics, Inc. (LRMR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jun 2014
Employees
65.00
Website
https://www.larimartx.comCEO
Carole S. Ben-Maimon
Description
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
LRMR Financial Timeline
Browse a chronological timeline of Larimar Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.39.
Earnings released on 14 May 2026
EPS came in at -$0.31 surpassing the estimated -$0.53 by +41.51%.
Earnings released on 19 Mar 2026
EPS came in at -$0.73 falling short of the estimated -$0.44 by -65.91%.
Earnings released on 5 Nov 2025
EPS came in at -$0.61 falling short of the estimated -$0.39 by -56.41%.
Earnings released on 14 Aug 2025
EPS came in at -$0.41 surpassing the estimated -$0.47 by +12.77%.
Earnings released on 30 Apr 2025
EPS came in at -$0.46 falling short of the estimated -$0.42 by -9.52%.
Earnings released on 24 Mar 2025
EPS came in at -$0.45 falling short of the estimated -$0.29 by -55.17%, while revenue for the quarter reached $241.00k .
Earnings released on 30 Oct 2024
EPS came in at -$0.24 surpassing the estimated -$0.37 by +35.14%.
Earnings released on 7 Aug 2024
EPS came in at -$0.34 falling short of the estimated -$0.32 by -6.25%.
Earnings released on 9 May 2024
EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%.
Earnings released on 14 Mar 2024
EPS came in at -$0.30 falling short of the estimated -$0.25 by -20.00%.
Earnings released on 14 Nov 2023
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 10 Aug 2023
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 15 May 2023
EPS came in at -$0.15 surpassing the estimated -$0.25 by +40.00%.
Earnings released on 14 Mar 2023
EPS came in at -$0.21 surpassing the estimated -$0.78 by +73.08%.
Earnings released on 10 Nov 2022
EPS came in at -$0.37 surpassing the estimated -$0.50 by +26.00%.
Earnings released on 11 Aug 2022
EPS came in at -$0.47 surpassing the estimated -$0.62 by +24.19%.
Earnings released on 12 May 2022
EPS came in at -$0.49 surpassing the estimated -$0.62 by +20.97%.
Earnings released on 25 Mar 2022
EPS came in at -$0.50 surpassing the estimated -$0.72 by +30.56%.
Earnings released on 12 Nov 2021
EPS came in at -$0.92 falling short of the estimated -$0.62 by -48.39%.
Earnings released on 12 Aug 2021
EPS came in at -$0.79 falling short of the estimated -$0.73 by -8.22%.
LRMR Stock Performance
Access detailed LRMR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
